Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

The efficacy and safety of sodium tanshinone ⅡA sulfonate injection in the treatment of unstable angina pectoris: A systematic review and meta-analysis

Abstract

Objective

To systematically evaluate the efficacy and safety of Sodium tanshinone ⅡA sulfonate injection (STS) in the treatment of unstable angina pectoris (UAP).

Methods

CNKI, Wanfang, VIP, CBM, PubMed, Cochrane Library, Web of Science, Embase were searched by computer. The research covers the clinical randomized controlled trials of STS in the treatment of unstable angina pectoris published from the establishment of the library to January 31, 2023. Two researchers independently screened the literature, extracted data and evaluated the risk of research bias, and then conducted meta-analysis with RevMan5.3 software.

Results

A total of 37 randomized controlled trials were included, involving 3926 patients in total. Meta analysis results showed that, compared with conventional western medicine alone, STS combined with conventional western medicine could reduce the frequency (SMD = -2.61, 95%CI[-4.27, -0.96], P = 0.002) and duration (SMD = -4.01, 95%CI[-6.18, -1.84], P = 0.0003) of angina pectoris, improve ECG efficacy (OR = 3.61, 95%CI[2.79, 4.68], P<0.00001) and clinical symptom efficacy (OR = 4.02, 95%CI[3.32, 4.87], P<0.00001), reduce TG(SMD = -0.60, 95%CI[-1.04, -0.16], P = 0.008), TC(SMD = -3.86, 95%CI[-6.37, -1.34], P = 0.003), and LDL-C(SMD = -1.54, 95%CI[-2.67, -0.42], P = 0.007), decrease plasma viscosity(SMD = -1.02, 95%CI[-1.58, -0.47], P<0.0003), whole blood low shear viscosity(SMD = -0.85, 95%CI[-1.21, -0.49], P<0.00001), whole blood high shear viscosity(SMD = -0.82, 95%CI[-1.44, -0.20], P = 0.009), and erythrocyte aggregation index(SMD = -1.00, 95%CI[-1.75, -0.25], P = 0.009), and bring down CRP(SMD = -1.39, 95%CI[-1.91, -0.86], P<0.00001). The incidence of adverse reactions in the treatment group was higher than that in the control group (OR = 2.26, 95%CI[1.06, 4.85], P = 0.04). Neither of the two groups suffered from abnormal liver and kidney function during the study process.

Conclusion

STS combined with routine treatment has a definite clinical efficacy and certain safety in the treatment of UAP, but it needs to be further confirmed by high-quality and low-bias randomized controlled trials in the future.

Citation: Wu X, Fan M, Wei S, Guo D (2023) The efficacy and safety of sodium tanshinone ⅡA sulfonate injection in the treatment of unstable angina pectoris: A systematic review and meta-analysis. PLoS ONE 18(8): e0290841. https://doi.org/10.1371/journal.pone.0290841

Editor: Hean Teik Ong, HT Ong Heart Clinic, MALAYSIA

Received: April 7, 2023; Accepted: August 16, 2023; Published: August 31, 2023

Copyright: © 2023 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting Information files.

Funding: This study was funded/supported by the National Academic Schools of Traditional Chinese Medicine,(XSLP-2013-35).

Competing interests: The authors have declared that no competing interests exist.

1. Introduction

Unstable angina pectoris (UAP) is a common type of angina pectoris, it is caused by coronary artery stenosis, increased blood viscosity, and atheromatous plaque blocking the blood vessels. The main manifestation is that the anterior chest area suffers from repeated pain with increasing frequency and severity. With the development of the disease, it can cause acute myocardial infarction [1,2]. UAP is currently one of the common chronic diseases that seriously affect the health and quality of patients’ life, and modern medicine has greatly improved the treatment of this disease. Conventional methods include anticoagulation, antiplatelet aggregation drugs β-receptor blockers, nitrates, angiotensin converting enzyme inhibitors, statins and other drugs [3], but they come with problems such as prominent side effects and drug dependence.

According to its clinical symptoms and signs, Traditional Chinese Medicine (TCM) classifies UAP as "chest pain", "heartache", and "angina pectoris". In recent years, with the continuous development of TCM preparation technology, more and more TCM preparations have been used to treat unstable angina pectoris, and their efficacy and safety have also received widespread attention [4]. There have been extensive pharmacological research on Salvia miltiorrhiza, and its chemical components are mainly divided into fat-soluble component tanshinone and water-soluble component salvianolic acid. The most widely studied compound in modern times is tanshinone. Sodium tanshinone IIA sulfonate is a substance obtained by chemical modification of the monomer tanshinone IIA extracted from Salvia miltiorrhiza [5], which is a Chinese herbal extract found in China to treat coronary heart disease. With very good anti-myocardial ischemia and hypoxia effect, sodium tanshinone IIA sodium sulfonate (STS) can inhibit angiotensin, reduce the occurrence of myocardial remodeling, and improve the clinical symptoms of angina pectoris [6]. STS is administered by intravenous drip, which is more conducive to maintaining drug concentration, improving blood circulation, expanding coronary arteries, and reducing heart rate [7].

There have been frequent reports of randomized controlled clinical trial (RCTs) on the treatment of UAP with STS, but the quality of these studies is low and the conclusions are not completely consistent. Using the method of evidence-based medicine, the effectiveness and safety of STS in the treatment of unstable angina pectoris were systematically evaluated, in an effort to provide strong evidence support for clinical research and application.

2. Material and methods

The methodology of this study followed the Cochrane manual and the report outlined in this study complied with the PRISMA2020 checklist [8]. This system evaluation has been registered on the PROSPERO website with the registration number: PROSPERO CRD42022369967.

2.1 Search strategy

The retrieval was conducted from multiple databases such as CNKI, Wanfang, VIP, CBM, PubMed, Cochrane Library, Web of Science, and Embase, covering RCTs of STS in the treatment of UAP from the establishment of the database to the publication on January 31, 2023. The Chinese search terms included: "coronary heart disease", "angina pectoris", "unstable angina pectoris", "chest pain", "true heartache", "tanshinone IIA sodium sulfonate injection", "tanshinone injection", "randomized", and "randomized controlled trial"; and the English search terms include: "Unstable angina", "Angina pectoris", "Sodium tanshinone IIA sulfonate", "Tanshinone IIA sulfonate", "randomized controlled trial", and "randomized". The search strategy of combining subject word with free word was adopted, and adjustment was made where necessary according to different retrieval strategies of each database.

2.2 Inclusion criteria

2.2.1 The type of research.

STS combined with routine treatment for RCTs of UAP;

2.2.2 Research object.

All the patients were in compliance with the diagnostic criteria for unstable angina in the "Guidelines for Emergency Diagnosis and Treatment of Acute Coronary Syndrome (2019)", regardless of age, gender, course of disease, and other conditions.

2.2.3 Intervention study.

The control group was treated with routine treatment (RT), including regular rest, oxygen intake, nitric acid ester, β-receptor antagonists, antiplatelet agglutinating drugs, angiotensin converting enzyme inhibitors, calcium antagonists, and statins for treatment, and so on. The treatment group was treated with STS combined with the routine treatment.

2.2.4 Outcome indicators.

The main outcome indicators are electrocardiographic efficacy (ECG), frequency of angina attacks, and duration of angina attacks. The secondary outcome indicators are efficacy of clinical symptoms (total effective = significant + effective), blood rheology (plasma viscosity, whole blood low viscosity, whole blood high shear viscosity; red cell aggregation index), blood lipid [total cholesterol (TC), triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c)], C-reaction protein (CRP), and adverse reactions.

2.3 Exclusion criteria

  1. Non-clinical randomized controlled trial;
  2. The interventions fails to meet the inclusion criteria, the diagnosis is unclear, or there exists other serious diseases;
  3. The data is not rigorous or the effective outcome indicator information cannot be extracted;
  4. Repeated publications, reviews, and animal experiments.

2.4 Data management and analysis

The two researchers (MXF and XQW) independently read and selected the full text of the literature and extracted relevant information, including the basic information of the literature (author, publication time), the number of patients, intervention methods (intervention measures, dose, duration), outcome indicators, adverse reactions, and other specific content. Cross-check was performed and any differences that arises was referred to a third party (SNW) for discussion and evaluation, and information was extracted from the final literature. The included literature was evaluated based on the bias risk assessment tool for clinical randomized controlled trials in the Cochrane manual. The evaluation items involved random sequence generation methods, allocation concealment, blinding implementation of subjects and investigators, blinding implementation of outcome evaluators, incomplete outcome reports, selective reports, and other sources of bias. Each of the above items was rated as "low risk", "high risk", and "unclear".

2.5 Statistical analysis

Statistical analysis was conducted using RevMan5.3 software provided by the Cochrane system. The odds ratio (OR) was used as the combined statistic for counting data, and the mean difference (MD) was used as the combined statistic for measuring data. If different measurement methods or units were used, the standardized mean difference (SMD) was used as the combined statistic for measuring data, all expressed as 95% confidence interval (CI). The test for heterogenicity can be quantitatively judged by I2 and P values.When P > 0.1 and I2 ≤ 50%, the fixed effect model was used for meta analysis, otherwise the random effect model was used for combined effect quantity analysis. At the same time, subgroup analysis was used to explore the source of heterogeneity in outcome indicators with large heterogeneity, and then sensitivity analysis or descriptive analysis was conducted through a one-by-one exclusion method. When the number of included studies was greater than 10, a funnel map was drawn to further assess whether there was publication bias.

3. Results

3.1 Results of the literature search

A total of 849 articles were retrieved, 37 of which were finally included after screening [9–45], and 36 were written in Chinese and 1 in English. 3926 patients were involved, including 2161 patients in the treatment group and 1765 in the control group. The literature screening process is shown in Fig 1, and the basic information for the included studies is shown in Table 1.

thumbnail
Download:
Fig 1. PRISMA flow-chart of the study selection process.

https://doi.org/10.1371/journal.pone.0290841.g001

thumbnail
Download:
Table 1. Basic characteristic of include studies.

https://doi.org/10.1371/journal.pone.0290841.t001

3.2 Quality evaluation of literature

The Cochrane manual was used to assess the bias of the included literature. A total of 37 [9–45] articles were included, where 2 studies [17,27] used a random number table method, 1 study [28] used a computer-generated program randomization method, 1 study [25] mentioned random grouping according to the order of patient visits, 3 studies [13,36,39] mentioned random grouping according to the order of admission, and the remaining 30 studies all mentioned random grouping but failed to give specific description to the randomization methods. Besides, 7 studies [13,17,25,27,28,36,39] identified allocation considerations as high risk, 2 studies [10,45] mentioned the use of single blinding, and the specific assessment information of bias risk included in various studies was shown in Fig 2.

thumbnail
Download:
Fig 2. Bias risk assessment for individual studies.

https://doi.org/10.1371/journal.pone.0290841.g002

3.3 Meta analytic result

3.3.1 Main outcome indicators.

  1. (1)ECG efficacy:

19 studies [9,11,14,20,21,24,26,30,32–34,36,38–41,43–45] reported electrocardiographic efficacy, and heterogeneity testing showed that there was little heterogeneity between the studies (P = 0.91, I2 = 0). The fixed effect model was used for meta-analysis, and the results showed that the difference was statistically significant (OR = 3.61, 95% CI [2.79, 4.68], P < 0.00001), indicating that the treatment group received better efficacy in electrocardiogram improvement than the control group, as shown in Fig 3.

thumbnail
Download:
Fig 3. Meta-analysis of ECG efficacy.

https://doi.org/10.1371/journal.pone.0290841.g003

  1. (2)Frequency of angina pectoris attacks:

7 studies [9,10,13,16,22,26,40] reported the frequency of angina pectoris attacks, and the heterogeneity test showed that there was significant heterogeneity among the studies (P < 0.00001, I2 = 99%). Through subgroup analysis, sensitivity analysis, and full-text reading, no source of significant heterogeneity was found through factors such as dose and course of treatment. Therefore, a randomized response model was used for meta analysis, and the results showed that the difference was statistically significant (SMD = -2.61, 95% CI [-4.27, -0.96], P = 0.002), indicating that the treatment group received better efficacy in improving the frequency of angina attacks than the control group, as shown in Fig 4.

thumbnail
Download:
Fig 4. Meta-analysis off requency of angina attacks.

https://doi.org/10.1371/journal.pone.0290841.g004

  1. (3)Time of angina attack:

4 studies [9,16,26,40] reported the onset time of angina pectoris, and the heterogeneity test showed significant differences among the studies (P < 0.00001, I2 = 98%). The results of meta-analysis using a random effect model showed that the differences were statistically significant (SMD = -4.01, 95% CI [-6.18, -1.84], P = 0.0003). As shown in Fig 5, the treatment group received better efficacy in improving the duration of angina attack than the control group. Subgroup analysis of the treatment course was adopted to detect the cause of high heterogeneity, 2 articles [9,16] studied a treatment course of 14 days and found that the heterogeneity decreased significantly when the treatment course was 14 days (P = 0.95, I2 = 0), with a statistically significant difference (SMD = -5.78, 95% Cl [-6.08, -5.48], P < 0.00001), indicating that STS combined with routine treatment was superior to the routine treatment alone in reducing the onset time of angina pectoris. In comparison, 2 studies [26,40] with a non-14-day treatment course reported significant heterogeneity (P = 0.002, I2 = 89%), with statistically significant difference (SMD = -2.21, 95% Cl [-3.51, -0.92], P = 0.0008), indicating that STS combined with routine treatment has better efficacy in reducing the onset time of angina pectoris than the routine treatment alone. The subgroup analysis results show that the treatment effect is better when the course of treatment is set as 14 days, as shown in Fig 6.

thumbnail
Download:
Fig 5. Meta-analysis of angina pectoris attack time.

https://doi.org/10.1371/journal.pone.0290841.g005

thumbnail
Download:
Fig 6. Subgroup analysis of angina pectoris attack time.

https://doi.org/10.1371/journal.pone.0290841.g006

3.3.2 Secondary outcome indicators.

  1. (1)Blood rheology

9 studies [9,17,19,23,25,31,34,37,43] reported hemorheology, and the heterogeneity test showed that there was a large heterogeneity among the studies (P<0.00001, I2 = 90%). The random effects model was used for meta-analysis, and the results showed that the difference was statistically significant (SMD = -0.93, 95%CI [-1.20, -0.66], P<0.00001), and the treatment group received better efficacy than the control group in improving hemorheology: ①Plasma viscosity: 9 studies [9,17,19,23,25,31,34,37,43] reported plasma viscosity with high heterogeneity (P<0.00001, I2 = 93%), so random effects model was used for meta-analysis. The results showed that the difference was statistically significant(SMD = -1.02, 95%CI [-1.58, -0.47], P<0.0003), indicating that the treatment group received better efficacy than the control group in improving plasma viscosity; ②Whole blood low viscosity: 6 studies [9,17,19,25,31,37] reported whole blood low viscosity with high heterogeneity (P = 0.0003, I2 = 79%), and the random effects model was used for meta-analysis. The results showed that the difference was statistically significant(SMD = -0.85, 95%CI [-1.21, -0.49], P<0.00001), indicating that the treatment group received better efficacy than the control group in improving the whole blood low viscosity; ③ Whole blood high shear viscosity: 6 studies [9,17,19,25,31,37] reported whole blood high viscosity with high heterogeneity(P<0.00001, I2 = 91%), and the random effects model was used for meta-analysis. The results showed that the difference was statistically significant(SMD = -0.82, 95%CI [-1.44, -0.20], P = 0.009), indicating that the treatment group received better efficacy than the control group in improving the whole blood high viscosity; ④Red blood cell aggregation: 5 studies [9,17,23,37,43] reported red blood cell aggregation with high heterogeneity(P<0.00001, I2 = 94%), and the random effects model was used for meta-analysis. The results showed that the difference was statistically significant(SMD = -1.00, 95%CI [-1.75, -0.25], P = 0.009), indicating that the treatment group received better efficacy than the control group in improving the red blood cell aggregation Fig 7.

thumbnail
Download:
Fig 7. Meta-analysis of blood rheology.

https://doi.org/10.1371/journal.pone.0290841.g007

  1. (2) Blood lipid

5 studies [13,24,30,33,37] reported blood lipid with high heterogeneity (P<0.00001, I2 = 97%), and the random effects model was used for meta-analysis. The results showed that the difference was statistically significant (SMD = -1.15, 95%CI [-1.88, -0.42], P = 0.002), indicating that the treatment group received better efficacy than the control group in improving the blood lipid; ①TC: 4 studies [13,24,33,37] reported TC with high heterogeneity(P<0.00001, I2 = 98%), and the random effects model was used for meta-analysis. The results showed that the difference was statistically significant(SMD = -3.86, 95%CI [-6.37, -1.34], P = 0.003), indicating that the treatment group received better efficacy than the control group in improving the TC; ②TG: 5 studies [13,24,30,33,37] reported TG with high heterogeneity(P = 0.0003, I2 = 81%), and the random effects model was used for meta-analysis. The results showed that the difference was statistically significant (SMD = -0.60, 95%CI [-1.04, -0.16], P = 0.008), indicating that the treatment group received better efficacy than the control group in improving the TG; ③LDL-c: 4studies [13,24,30,33] reported LDL-c with high heterogeneity(P<0.00001, I2 = 95%), and the random effects model was used for meta-analysis. The results showed that the difference was statistically significant(SMD = -1.54, 95%CI [-2.67, -0.42], P = 0.007), indicating that the treatment group received better efficacy than the control group in improving the LDL-c; ④HDL-C: 4 studies [13,24,30,33] reported HDL-c with high heterogeneity, and there was no significant difference between the treatment group and the control group(P = 0.14>0.05) Fig 8.

thumbnail
Download:
Fig 8. Meta-analysis of blood lipid.

https://doi.org/10.1371/journal.pone.0290841.g008

  1. (3) CRP

9studies [19,20,24,25,28,34,41–43] reported CRP with high heterogeneity (P<0.00001, I2 = 89%), and the random effects model was used for meta-analysis. The results showed that the difference was statistically significant(SMD = -1.39, 95%CI [-1.91, -0.86], P<0.00001), indicating that the treatment group received better efficacy than the control group in improving the CRP Fig 9.

thumbnail
Download:
Fig 9. Meta-analysis of CRP.

https://doi.org/10.1371/journal.pone.0290841.g009

3.3.3 Adverse reactions.

10 studies [9,14,16,21,26,29,31,40,41,45] reported adverse reactions. According to the heterogeneity test, the heterogeneity among the studies was small(P = 0.56, I2 = 0%), so fixed effects model was used for meta-analysis. The results showed that the difference was statistically significant (OR = 2.26, 95%CI [1.06, 4.85], P = 0.04), indicating that the incidence of adverse reactions in the treatment group was higher than that in the control group. However, the adverse reactions in the two groups were alleviated without treatment after the slowing down of the dripping rate or drug withdrawal, which did not affect the study process. There were no significant changes in liver and kidney function before and after treatment in the two groups. The specific adverse reactions are shown in Table 2 and Fig 10.

thumbnail
Download:
Fig 10. Meta-analysis of adverse reactions.

https://doi.org/10.1371/journal.pone.0290841.g010

thumbnail
Download:
Table 2. Adverse reactions.

https://doi.org/10.1371/journal.pone.0290841.t002

3.4 Sensitivity analysis

Sensitivity analysis was conducted based on the meta-analysis results of TST in the treatment of UAP. All outcome indicators were removed on a one-by-one basis and no significant changes in outcome indicators were found in the re-analysis, indicating low sensitivity of the overall analysis results and high confidence with the outcome.

3.5 Bias risk assessment

Risk of publication bias was assessed for outcome indicators of more than 10 articles included in this meta-analysis, and funnel plots of ECG efficacy and clinical symptom efficacy were observed. It was found that the study sites were not completely symmetrical, suggesting the risk of publication bias Figs 11 and 12.

thumbnail
Download:
Fig 11. ECG efficacy funnel chart.

https://doi.org/10.1371/journal.pone.0290841.g011

thumbnail
Download:
Fig 12. Clinical efficacy funnel chart.

https://doi.org/10.1371/journal.pone.0290841.g012

4. Discussion

4.1 Result analysis

Meta-analysis and systematic review have shown that the TST in combination with routine treatment can reduce the frequency and duration of angina attacks, improve ECG efficacy and clinical symptoms, reduce TG, TC, LDL-C, lower whole blood low shear viscosity, whole blood high shear viscosity, plasma viscosity as well as red blood cell aggregation. The effect of CRP reduction was superior to that of routine treatment alone. As for the improvement of HDL-C, no ideal results were obtained due to the inadequate quantity and uneven quality of the included studies and further confirmation was needed. Subgroup analysis showed that 14 days of treatment was more effective in reducing the duration of angina attack. A few cases of adverse reactions occurred in the two groups, and the incidence of adverse reactions in the treatment group was higher than that in the control group. However, no abnormal liver and kidney function occurred in each study, which did not affect the research process. The clinical application of TST in the treatment of UAP is safe and effective, but the quality of the included literature is low. Therefore, higher quality randomized controlled clinical trials are needed in the future to further demonstrate the effectiveness and safety of TST and provide better clinical guidance.

4.2 Limitations

This study systematically evaluated the efficacy and safety of STS in combination with routine treatment for UAP, with the following limitations: ① Of the 37 articles included, only 2 were randomized with numerical tables, 1 was randomized with a computer-generated program, 1 was randomized in the order of patient visits, 3 were randomized in the order of admission, and remainder just mentioned randomization, without specifying which randomization method was adopted. Only 2 articles used a single-blind experimental design. ② The quality of the included literature is uneven, and the heterogeneity in age, sex, intervention course, and dose may also be important factors leading to biases. ③ There was a lack of long-term follow-up study and therefore an absence of long-term observation data.

4.3 Clinical significance

STS is mainly used in the clinical treatment of cardiovascular and cerebrovascular diseases, such as coronary heart disease and angina pectoris [46], which can effectively improve angina pectoris related indexes, optimize hemorheology indexes, improve blood lipid and reduce CRP level [47]. The significance of this systematic review mainly lies in the comprehensive collection of all Chinese and English literatures on STS combined with routine treatment in the UAP treatment. After data screening and meta-analysis, a large-sample study result was finally obtained, which is more convincing and reliable than single-sample study [48].

In order to further strengthen the evidence, future studies should develop rigorous implementation plans, design large-sample, multi-center and long-term clinical randomized controlled trials according to evidence-based medicine standards, and pay attention to the correct and reasonable implementation of randomization, allocation concealment and blind methods, so as to reduce the biases in selectivity, implementation, measurement and other aspects. For the treatment of UAP by STS, different doses and courses of medication can produce different curative effects on patients. Normative standards of dosage and course of treatment should be formulated in the included studies according to the use method of STS instructions and suitable population. In addition, the rate of drops should be controlled, with special attention paid to the allergic population, so as to improve the active treatment of adverse reactions in the treatment process. Records and reports should be made in a more detailed manner to improve the quality of evidence [49].

5. Conclusion

In conclusion, based on the available evidence, the STS in combination with routine treatment may be promisingly effective and safe in the treatment of UAP However, the overall quality of the included literature is low, and higher quality clinical randomized controlled trial are needed in the future to further explore the effectiveness and safety of STS, so as to provide higher quality evidence for clinical work.

Supporting information

S1 Checklist. PRISMA 2009 checklist.

https://doi.org/10.1371/journal.pone.0290841.s001

(DOC)

References

  1. 1. Zhang X, Wu J, Zhang B, et al. Danshenchuanxiongqin injection in the treatment of unstable angina pectoris: a systematic review and Meta-analysis[J]. J Tradit Chin Med, 2016,36(2):144–150.
  2. 2. Yeghiazarians Y, Braunstein J B, Askari A, et al. Unstable angina pectoris[J]. N Engl J Med, 2000,342(2):101–114.
  3. 3. Mayer M. Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes[J]. Am J Emerg Med, 2017,35(3):502–507.
  4. 4. Wu J R, Liu S, Zhang X M, et al. Danshen injection as adjuvant treatment for unstable angina pectoris: A systematic review and meta-analysis[J]. Chin J Integr Med, 2017,23(4):306–311.
  5. 5. Zhou Z Y, Zhao W R, Zhang J, et al. Sodium tanshinone IIA sulfonate: A review of pharmacological activity and pharmacokinetics[J]. Biomed Pharmacother, 2019,118:109362.
  6. 6. Tan D, Wu J R, Zhang X M, et al. Sodium Tanshinone II A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials[J]. Chin J Integr Med, 2018,24(2):156–160.
  7. 7. Zheng G. Expert suggestion on clinical application of tanshinone Ⅱ_A sodium sulfonate injection [J]. Chinese Journal of Cardio-Cerebrovascular Diseases in Geriatrics,2015,17(12):1261–1264.
  8. 8. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021 Mar 29;372:n160. pmid:33781993
  9. 9. Yong Zhang, Zhongchao Cao, Binsong Liu. Clinical effect of tanshinone Ⅱ_A sodium sulfonate on unstable angina pectoris [J]. Journal of Inner Mongolia Medical University,2013,35(S2):382–384.
  10. 10. Rongjun Li, Kuisong Zhang. Effects of tanshinone Ⅱ_A sodium sulfonate injection on platelet activation in patients with unstable angina pectoris syndrome [J]. Chinese Pharmaceutical Industry,2017,26(10):63–66.
  11. 11. Peiqi Li, Peng Wang, Zhiqiang Li. Effect of tanshinone ⅡA sulfonate on myocardial ischemia in patients with unstable angina pectoris [J]. Chinese Medical Guide,2012,10(32):220–221.
  12. 12. Yan Xue, Hongli Duan, Juanhong Ren. Clinical observation of 80 cases of unstable angina pectoris treated with tanshinone ⅡA sulfonate [J]. Jilin Medicine,2012,33(35):7694.
  13. 13. Zhankui Jin. Therapeutic effect of tanshinone ⅡA sodium sulfonate on 100 cases of unstable angina pectoris [J]. Chin J Medica Guide,2016,14(23):177–178.
  14. 14. JU H. Therapeutic effect of tanshinone ⅡA sulfonate on unstable angina pectoris [J]. Jilin Medical Journal,2013,34(08):1475.
  15. 15. Zhenhua Liu. Clinical effect of tanshinone ⅡA sulfonate on unstable angina pectoris [J]. Clinical of Integrated Traditional and Western Medicine,2014,14(04):56–57.
  16. 16. Qingxia Si. Effect of tanshinone ⅡA sulfonate on unstable angina pectoris of acute coronary syndrome in 566 patients [J]. Journal of Medical Forum,2012,33(12):56–57.
  17. 17. Degang Li, Daozhen Xu. Clinical effect of tanshinone ⅡA sulfonate injection on unstable angina pectoris in senile patients and its improvement on hemorheology [J]. Modern Diagnosis and Therapy,2017,28(04):652–654.
  18. 18. Liya Huang, Kailian Xu, Yandao Fu. Clinical effect of tanshinone ⅡA sulfonate injection on unstable angina pectoris [J]. Chin J Medical Guide,2013,11(33):498–499.
  19. 19. Fenglin Zhao, Xianbin Lu, Deqian Yang, Lumei Huang. Clinical observation on the treatment of unstable angina pectoris by tanshinone ⅡA sodium sulfonate injection [J]. Chinese Emergency of Traditional Chinese Medicine,2012,21(11):1844–1845.
  20. 20. Fei He, Xinlang Zhou. Clinical effect of tanshinone ⅡA sulfonate injection on unstable angina pectoris [J]. Modern Practical Medicine,2014,26(07):815–816.
  21. 21. Zhaohui Zhang, Hui Zhang. Clinical effect of tanshinone ⅡA sulfonate injection on unstable angina pectoris [J]. Chinese Journal of Disability Medicine,2013,21(03):108–109.
  22. 22. Jianming Zou. Clinical effect of tanshinone ⅡA sulfonate injection on unstable angina pectoris [J]. Journal of Cardiovascular Diseases,2017,5(31):4–5+7.
  23. 23. Fengdong Du. Effect of tanshinone ⅡA sulfonate injection on unstable angina pectoris of coronary heart disease [J]. Chinese medicine guidelines, 2018 (12): 189–190. The 2018.12.151.
  24. 24. Yang Gao, Guangbin Liu, Jun Wang. Treatment of unstable angina pectoris by tanshinone combined with nitrate [J]. Clinical Medicine Practice,2014,23(04):258–260.
  25. 25. Hongyan Wang. Clinical observation of Tanshinone injection in treatment of unstable angina pectoris in elderly patients [J]. Western Chinese Medicine,2013,26(05):5–6.
  26. 26. Chen G. Therapeutic effect of combined tanshinone ⅡA sulfonate injection on unstable angina pectoris [J]. Chinese Journal of Pharmaceutical Economics,2013(S3):63–64.
  27. 27. Zhengju Fan, Ming Yang, Yuan Fu, Hao Deng. To explore the therapeutic effect of tanshinone ⅡA sulfonate injection on unstable angina pectoris of coronary heart disease and its effect on platelet activation function [J]. Chinese Journal of Biochemical Drugs,2016,36(03):140–142.
  28. 28. Zhang H, Long M, Wu Z, Han X, Yu Y. Sodium tanshinone IIA silate as an add-on therapy in patients with unstable angina pectoris. J Thorac Dis. 2014 Dec; 6 (12): 1794–9. pmid:25589975
  29. 29. Li W. Clinical observation of tanshinone ⅡA sulfonate combined with low molecular weight heparin in treatment of unstable angina pectoris in senile patients [J]. Chinese Journal of Medical Sciences,2012,2(16):52–53+55.
  30. 30. Jingnan Huang. Clinical observation on the treatment of unstable angina pectoris by tanshinone Ⅱa sulfonate injection [J]. Contemporary Medicine,2012,18(02):138.
  31. 31. Xing Pei, Gang Chen. Treatment of unstable angina pectoris with tanshinone ⅡA sodium sulfonate combined with Western medicine in 36 cases [J]. Shaanxi Journal of Traditional Chinese Medicine,2009,30(10):1276–1278.
  32. 32. Junhui Wang. Clinical study of tanshinone Ⅱ_A in the treatment of unstable angina pectoris [J]. Modern Distance Education of Chinese Traditional Medicine,2010,8(22):158–159.
  33. 33. Ge Hai-zhu CHENG Yao-nan, Qin Huan-yi. Clinical observation on the treatment of unstable angina pectoris with tanshinone ⅡA sulfonate [J]. Chinese Journal of Refractory Diseases,2010,9(03):201–202.
  34. 34. Ning Yang, Fuxian Ren. Clinical application of tanshinone ⅡA sulfonate in the treatment of unstable angina pectoris [J]. Chinese Modern Doctors,2010,48(21):47–49.
  35. 35. Huiling Liu, Xiaohui Yang. Effect of tanshinone ⅡA sulfonate on unstable angina pectoris [J]. Chinese Journal of Medical Innovation,2010,7(13):37.
  36. 36. He Huang, Rong Zhou. Effect of tanshinone ⅡA sulfonate combined with isosorbide mononitrate on unstable angina pectoris [J]. International Medical Journal,2011,30(11):136.
  37. 37. Wanquan Luo, Minli Li. Therapeutic effect of tanshinone ⅡA sulfonate on unstable angina pectoris [J]. Chinese Journal of Medical Sciences,2011,1(11):50+54.
  38. 38. Weijun Song. Effect of tanshinone ⅡA sulfonate injection on unstable angina pectoris of coronary heart disease [J]. China Health Industry,2011,8(29):52.
  39. 39. Zhang W. Therapeutic effect of tanshinone ⅡA sulfonate injection on unstable angina pectoris of coronary heart disease [J]. Chinese Journal of Modern Medicine,2011,18(35):72–73.
  40. 40. Xiaolong Chen, Jianzhong Yang, Huisheng Xiong, Bo Long. Clinical study on the treatment of unstable angina pectoris of coronary heart disease with tanshinone ⅡA sulfonate [J]. Chongqing Medical Journal,2008(02):168–169+171.
  41. 41. Yuwang Qin, Xinbin He, Zhenqian Zhang. Clinical effect of tanshinone ⅡA sulfonate injection on unstable angina pectoris [J]. Journal of Integrated Traditional Chinese and Western Medicine,2008(24):3768–3769.
  42. 42. Geping Xu, Hua Su. Effect of tanshinone on inflammatory factors in patients with unstable angina pectoris [J]. Hainan Medicine,2008(03):31–33.
  43. 43. Ganlan Wang, Xiujuan Deng, Xiaoqiu Li, Xintong Chen. Effects of tanshinone injection on CRP and D-dimer in patients with unstable angina pectoris [J]. New Chinese Medicine,2007(07):16–17.
  44. 44. Jianghua Ma, Weiping Xiong, Fengwei Wan, Mei Hua. Treatment of unstable angina pectoris by tanshinone ⅡA sulfonate combined with Xinkang [J]. Chinese Modern Doctor,2007(14):97+105.
  45. 45. Huarui Zhang, Li Sun, Yuchen Li, Yukun Jin. Effect of tanshinone Ⅱ_A sodium sulfonate injection on unstable angina pectoris [J]. Tianjin Pharmacy,2006(06):31–32.
  46. 46. Zhang D, Wu J, Liu S, et al. Salvianolate injection in the treatment of unstable angina pectoris: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2016,95(51):e5692.
  47. 47. Xu J, Zhang C, Shi X, et al. Efficacy and Safety of Sodium Tanshinone IIA Sulfonate Injection on Hypertensive Nephropathy: A Systematic Review and Meta-Analysis[J]. Front Pharmacol, 2019,10:1542.
  48. 48. Song H, Wang P, Liu J, et al. Panax notoginseng Preparations for Unstable Angina Pectoris: A Systematic Review and Meta-Analysis[J]. Phytother Res, 2017,31(8):1162–1172.
  49. 49. Maoxia Fan, Ying Tian, Dong Guo, Jisen Zhao, Yongcheng Liu. Efficacy and safety of Shugan Jieyu Capsule in treating essential hypertension and accompanying symptoms [J]. Hebei Journal of Traditional Chinese Medicine, 201,43(10):1728–1737.